Neha Pathak, MD, FACP, DipABLM: Welcome to the WebMD Health Discovered Podcast. I'm Dr Neha Pathak, WebMD's, Chief Physician Editor for Health and Lifestyle Medicine. Many of us have talked to our ...
MedPage Today on MSN
Amid Opioid Addiction Treatment, Losing Insurance Tied to Mortality Risk
Health insurance loss, changes "may undermine continuity of critical treatment," researche ...
Please provide your email address to receive an email when new articles are posted on . Among adults aged 18 to 44 years, the rate of serious falls was 5.5 times higher in the first 28 days after ...
Socially vulnerable counties face higher overdose deaths and treatment needs, findings that could help prioritize funding and programming responses, according to Rutgers researchers Opioids such as ...
Please provide your email address to receive an email when new articles are posted on . Opioids and NSAIDs demonstrated a similar risk for MACE in patients with rheumatoid arthritis. Death and venous ...
Research involving over 2.1 million veterans indicates that LTOT is significantly linked to infection-related dental outcomes, even after adjusting for comorbidities.
Older people with chronic pain expressed views about opioid use that often sharply differed from those of primary care doctors, an interview-based study indicated. When asked about the risks ...
As opioid pain medications continue being prescribed for chronic and severe pain, understanding their risks becomes increasingly crucial. While these pills may offer temporary relief, their potential ...
Infants exposed to opioids and psychotropic drugs during pregnancy have a 30% to 60% higher risk of experiencing neonatal withdrawal, a study has found. That risk doubles when multiple psychotropic ...
Prescription opioid use increases the risk for major depressive disorder (MDD) and anxiety and stress-related disorders (ASRD), new genetic evidence shows. The findings also suggest MDD is a potential ...
The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results